XCNQ
GTII
Market cap1.23bUSD
Oct 30, Last price
8.70CAD
1D
-3.33%
1Q
-13.78%
Jan 2017
-40.91%
Name
Green Thumb Industries Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Green Thumb Industries Inc. (GTI) is an American enterprise primarily involved in the production, distribution, and retail of diverse cannabis offerings throughout the United States, serving both medicinal and recreational consumers. Its extensive product catalog features raw cannabis flower, alongside a wide array of processed and packaged goods such as pre-rolls, concentrated extracts, vaporizers, liquid tinctures, edible treats, and topical applications. These items are marketed under notable brands including Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM. While GTI primarily supplies its merchandise to independent retail establishments, it also engages in direct-to-consumer sales via its proprietary network of stores. As of April 11, 2022, the company managed and operated 77 retail locations across the U.S. Established in 2014, Green Thumb Industries Inc. maintains its corporate headquarters in Chicago, Illinois.
Key people
Chairman of the Board, Chief Executive Officer, Founder · since 2018
Mathew Faulkner
Chief Financial Officer · since 2023
Bret Kravitz
General Counsel, Secretary · since 2023
Anthony Georgiadis
President, Director · since 2023
Jeffrey Goldman
Director · since 2023
Dawn Barnes
Independent Director · since 2023
Ethan Nadelmann
Independent Director · since 2023
Richard Reisin
Independent Director · since 2023
Hannah Ross
Independent Director · since 2023
Legal address
250 Howe Street, 20th Floor
Vancouver, BC V6C 3R8
CA
Vancouver, BC V6C 3R8
CA
Headquarters
Suite 2200, HSBC Building, 885 West Georgia Street
Vancouver, BC, ON V6C 3E8
CA
Vancouver, BC, ON V6C 3E8
CA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑02 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||